Athérosclérose au cours du lupus érythémateux systémique

Mezalek, Z. Tazi; Harmouche, H.; Ammouri, W.; Maamar, M.; Adnaoui, M.; Cacoub, Patrice

doi:10.1016/j.lpm.2014.01.021

Cited by 13 publications

(12 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most studies reveal that relative risk of myocardial infarction exceeds 5 to 8 times compared to general population 4. Studies have shown that the prevalence of dyslipidemia in lupus patients ranges from 36% at diagnosis to 60% or even higher after 3 years 5.…”

Section: Introductionmentioning

confidence: 99%

Frequency of Dyslipidemia in patients with Lupus Nephritis

et al. 2017

View full text Add to dashboard Cite

Objective:To determine the frequency of dyslipidemia in patients with lupus nephritis and its association with the degree of proteinuria.Methods:This cross-sectional analytic study included 65 patients who fulfilled the ACR (American College of Rheumatology) criteria for SLE and had renal involvement, presenting to the Division of Rheumatology, Fatima Memorial Hospital (FMH), and Lahore from 21st Sep 2016 to 20th Dec 2016. After 12 hours overnight fast their blood samples were assessed for total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL). Patient demographic variables (age, sex) and disease characteristics (disease duration, degree of proteinuria, steroid dose) were noted. Patients were categorized into two groups on the basis of degree of proteinuria: having proteinuria >1gm or ≤ 1gm. Data was analyzed using SPSS version 22. Individual lipid profiles were correlated with the degree of proteinuria.Results:Most common lipid abnormality found in our study was hypertriglyceridemia (58.5%). Total Cholesterol and LDL-C was high in 55.4% and 30.8% subjects respectively. Low HDL was found in 21.5% subjects. Increased frequency of dyslipidemia was noticed in those subjects who had proteinuria >1gm (P value < 0.05).Conclusion:Dyslipidemia was observed in a high frequency in patients with lupus nephritis and was strongly associated with their degree of proteinuria.

show abstract

Section: Introductionmentioning

confidence: 99%

Frequency of Dyslipidemia in patients with Lupus Nephritis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…[ 49 - 51 ]. Antimalarials have an anti-thrombotic, anti-inflammatory effect and control dyslipidemia [ 52 ]. Moreover, by blocking toll like receptors 7 and 9, hydroxychloroquine inhibits interferon alpha production which plays a pathogenetic role in SLE pathogenesis [ 53 ].…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, by blocking toll like receptors 7 and 9, hydroxychloroquine inhibits interferon alpha production which plays a pathogenetic role in SLE pathogenesis [ 53 ]. Mycophenolate mofetil reduces the activation of T lymphocytes and increases the presence of regulatory T lymphocytes in carotid plaques [ 52 ]. An animal model of SLE showed that Atorvastatin reduces the level of autoantibodies and improves proteinuria and renal histology, however, there is still no general consensus for its extensive use in SLE patients [ 52 ].…”

Section: Introductionmentioning

confidence: 99%

“…Mycophenolate mofetil reduces the activation of T lymphocytes and increases the presence of regulatory T lymphocytes in carotid plaques [ 52 ]. An animal model of SLE showed that Atorvastatin reduces the level of autoantibodies and improves proteinuria and renal histology, however, there is still no general consensus for its extensive use in SLE patients [ 52 ]. Treatment with non steroidal anti-inflammatory drugs (NSAIDs) may increase cardiovascular risk (rofecoxib is associated with a greater risk of myocardial infarction, ibuprofen is associated with a higher risk of stroke, diclofenac with higher cardiovascular toxicity, naproxen seems to be the least harmful [ 54 ] though it can worsen kidney function.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Systemic lupus erythematosus and thrombosis

2015

View full text Add to dashboard Cite

Systemic Lupus Erythematosus (SLE) is an acquired, multiorgan, autoimmune disease. Clinical presentation is extremely variable and heterogeneous. It has been shown that SLE itself is an independent risk factor for developing both arterial and venous thrombotic events since SLE patients have an Odds Ratio (OR) for thrombosis that varies depending on the clinical and laboratory characteristics of each study cohort. The risk of developing a thrombotic event is higher in this setting than in the general population and may further increase when associated with other risk factors, or in the presence of inherited or acquired pro-thrombotic abnormalities, or trigger events. In particular, a striking increase in the number of thrombotic events was observed when SLE was associated with antiphospholipid antibodies (aPL). The presence of aPLs has been described in about 50% of SLE patients, while about 20% of antiphospholipid syndrome (APS) patients have SLE. While APS patients (with or without an autoimmune disease) have been widely studied in the last years, fewer studies are available for SLE patients and thrombosis in the absence of APS. Although the available literature undoubtedly shows that SLE patients have a greater prevalence of thrombotic events as compared to healthy subjects, it is difficult to obtain a definite result from these studies because in some cases the study cohort was too small, in others it is due to the varied characteristics of the study population, or because of the different (and very copious) laboratory assays and methods that were used. When an SLE patient develops a thrombotic event, it is of great clinical relevance since it is potentially life-threatening. Moreover, it worsens the quality of life and is a clinical challenge for the clinician.

show abstract

“…Elle est estimée entre 10 et 20% de la mortalité globale au cours du lupus [ 1 – 3 ]. Le risque d′évènements cardio-vasculaires est 2 à 3 fois plus élevé au cours de cette maladie associé à une mortalité coronarienne et neuro-vasculaire augmentées par rapport à des populations appariées pour l′âge et le sexe [ 1 , 2 ]. Ainsi, plusieurs études ont montré que le risque d′infarctus est multiplié par 2 à 10 au cours du lupus comparativement à des témoins appariés et que le risque d′accident vasculaire cérébral est multiplié par 7,9 [ 4 , 5 ].…”

Section: Introductionunclassified

Facteurs de risque cardiovasculaires au cours du lupus systémique

et al. 2015

View full text Add to dashboard Cite

Cette étude a pour objectif d’évaluer la fréquence des facteurs de risque cardiovasculaires au cours du lupus et de préciser leur prévalence. Etude rétrospective portant sur 250 patients ayant un lupus, diagnostiqué selon les critères de l'ACR, hospitalisés entre 1970 et 2013. Les données cliniques et para cliniques ont été recueillies à partir des observations médicales. Il s'agit de 228 femmes et 22 hommes d’âge moyen au diagnostic du lupus de 30, 32 ans (extrêmes: 16-69). La durée moyenne du suivi des patients était de 64 mois (extrêmes: 7 jours- 382mois). Quatre vingt dix patients (36%) étaient hypertendus, 74% avaient une hypercholestérolémie et 22% étaient diabétiques. Pour les autres facteurs de risque cardiovasculaire traditionnels, un âge > 50 ans a été retrouvé dans 40% des cas, le sexe masculin dans 8% des cas, l'obésité dans 76% des cas et le tabagisme dans 11% des cas. Les facteurs de risque surajoutés sont représentés par la présence des anticorps antiphospholipides (47% des cas), la néphropathie lupique (49% des cas), l'insuffisance rénale (42% des cas), la corticothérapie au long cours (74% des cas) et la chronicité de la maladie dans 35% des cas. Les complications cardiovasculaires retrouvées dans notre série étaient: les accidents vasculaires cérébraux (2%) et l'insuffisance coronarienne (5,6%). Devant l'importance du risque cardiovasculaire au cours du lupus, une surveillance rapprochée des facteurs de risque cardio-vasculaires semble primordiale chez les lupiques.

show abstract

Athérosclérose au cours du lupus érythémateux systémique

Cited by 13 publications

References 106 publications

Frequency of Dyslipidemia in patients with Lupus Nephritis

Frequency of Dyslipidemia in patients with Lupus Nephritis

Systemic lupus erythematosus and thrombosis

Facteurs de risque cardiovasculaires au cours du lupus systémique

Contact Info

Product

Resources

About